Get started
Author

Warren Mason

Emerging Biomarkers in Glioblastoma
2013 · Mairéad McNamara, Solmaz Sahebjam, et al. · Cancers · 97
PDF
Ltbk-01. Phase 3 Stellar Study Shows Eflornithine Improves Overall Survival (os) and Progression Free Survival (pfs) in Patients With Recurrent 2021 Who Astrocytoma, Idh-mutant Grade 3
2024 · Howard Colman, Giuseppe Lombardi, et al. · Neuro-Oncology · 2
PDF
Biom-31. Plasma Cell-free Dna Methylome Predicts Response to Combined Parp and Immune Checkpoint Inhibition in Idh-mutant Glioma
2025 · Yosef Ellenbogen, Kevin Wang, et al. · Neuro-Oncology · 1
PDF
Immu-18. Favorable Outcome in Replication Repair Deficient Hypermutant Brain Tumors to Immune Checkpoint Inhibition: an International Rrd Consortium Registry Study
2020 · Eric Bouffet, Sumedha Sudhaman, et al. · Neuro-Oncology · 1
PDF
Exploratory Analyses from the Phase Three INDIGO Study Suggest Potential Mechanism of Seizure Control Through Tumor Volume Reduction Under Treatment With Vorasidenib (S28.002)
2026 · Katherine Peters, Ingo Mellinghoff, et al. · Neurology
Treatment patterns and outcomes in high-risk WHO grade 2 diffuse glioma: a multicentre retrospective cohort study
2026 · Jason L. Jia, Bader Alshamsan, et al. · Journal of Neuro-Oncology
Association of proton pump inhibitor use with outcome of patients with newly diagnosed glioblastoma
2025 · Michael Weller, Debaleena Sain, et al. · Journal of the Neurological Sciences
QOL-22. Prognostic associations of the G8 geriatric screening tool in the EORTC Brain Tumor Group trials 1608 and 1709 in newly diagnosed glioblastoma
2025 · Emilie Le Rhun, Luc Boone, et al. · Neuro-Oncology
PDF
Ctni-58. Updated Results of Phase 3 Stellar Trial: Eflornithine Improves Overall Survival and Blinded Independent Central Review Determined Progression Free Survival in Patients With Recurrent Who 2021 Grade 3 Idh-mutant Astrocytoma
2025 · Howard Colman, Giuseppe Lombardi, et al. · Neuro-Oncology
PDF
INNV-04. Association of proton pump inhibitor use with outcome of patients with newly diagnosed glioblastoma
2025 · Emilie Le Rhun, Debaleena Sain, et al. · Neuro-Oncology
PDF
INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation
2024 · Timothy F. Cloughesy, Martin van den Bent, et al. · Brain and Spine
Immu-20. Immune and Tumor Biomarkers of Outcome in Replication Repair Deficient Brain Tumors Treated With Immune Checkpoint Inhibitors: Updates From the International Replication Repair Deficiency Consortium
2019 · Eric Bouffet, Sumedha Sudhaman, et al. · Neuro-Oncology
PDF
Works count: 12
Citation count: 101
H-index: 2
I10-index: 1
Year
Topic
Type